GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Liabilities | ₹14,925 Cr | ₹13,309 Cr | ₹17,566 Cr | ₹15,397 Cr | ₹14,069 Cr |
What is the latest Total Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Total Liabilities |
|---|---|
| Mar2025 | ₹14,925 Cr |
| Mar2024 | ₹13,309 Cr |
| Mar2023 | ₹17,566 Cr |
| Mar2022 | ₹15,397 Cr |
| Mar2021 | ₹14,069 Cr |
How is Total Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Total Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹14,925 Cr | 12.15 | |
| Mar2024 | ₹13,309 Cr | -24.23 | |
| Mar2023 | ₹17,566 Cr | 14.08 | |
| Mar2022 | ₹15,397 Cr | 9.44 | |
| Mar2021 | ₹14,069 Cr | - | |
Compare Total Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹60,864.9 Cr | 0.6% | -7.2% | 33.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹432,036.0 Cr | 0.8% | -4.2% | 7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹178,218.0 Cr | 1.1% | -0.7% | -1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹151,099.0 Cr | 0% | 1.3% | 40.1% | Stock Analytics | |
| CIPLA | ₹110,897.0 Cr | -0.3% | -4.1% | -8.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,591.0 Cr | 0.4% | -4.5% | -5.2% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 0.6% |
-7.2% |
33.4% |
| SENSEX | 3.9% |
1.9% |
-6.8% |
You may also like the below Video Courses